Novamed

Company Overview

Snapshot

Founded in December 1995, Novamed operated with 11–50 employees. The company was acquired by Simplivia Healthcare in January 2021, marking a significant exit in the health tech sector.

Business overview

Novamed specializes in the development of proprietary diagnostic systems for the rapid detection of microorganisms. Its core technology includes FDA-approved culture devices like DipStreak and Diaslide for urinary tract infections, and NovaStreak for food and dairy product analysis. The company also developed NovaCup, an innovative urine collection cup with an integrated urinalysis testing strip for point-of-care or home use, providing quantifiable results via a digital reader or smartphone application. Novamed serves markets in Europe, China, and Russia, operating within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Devices.

Strategic signal

In January 2021, Novamed was acquired by Simplivia Healthcare. This acquisition highlights the strategic value of Novamed's diagnostic technologies and its potential for broader market integration, signaling a successful exit for the company and a strengthening of Simplivia Healthcare's portfolio in the diagnostics space.

Company Intelligence Q&A

What is NovaCup?

NovaCup is an innovative urine collection cup developed by Novamed with an integrated full-panel urinalysis testing strip. It provides quantifiable results for point-of-care or home users without needing to send samples to a laboratory, with results automatically read by a digital reader or smartphone application.

When was Novamed acquired?

Novamed was acquired by Simplivia Healthcare in January 2021.

What diagnostic systems has Novamed developed?

Novamed has developed several proprietary diagnostic systems, including the patented and FDA-approved DipStreak and Diaslide culture devices for rapid diagnosis of urinary tract infections, and NovaStreak for detecting microorganisms in food and dairy products.

Did Novamed participate in COVID-19 related initiatives?

In March 2020, Novamed partnered with BATM to develop a COVID-19 home rapid test kit. Additionally, in October 2020, UHWI researched COVID-19 pool-testing in partnership with Novamed.

What is the primary focus of Novamed's diagnostic products?

Novamed's primary focus is on microorganism diagnostic systems, particularly for rapid detection in urinary tract infections, food and dairy products, and home-based urinalysis.